Blandine Lacroix is Senior Vice President, Strategy and Rare Disease
since January 2023. In her role, she is responsible for leading the
development of the U.S. organization's long term enterprise and future
business strategy, in addition to leading the U.S. Rare Disease
strategic efforts with a commercial team that specializes in
treatments for people with hemophilia and growth hormone-related
disorders, while preparing for future opportunities in other rare
bleeding disorders, rare endocrine disorders and ultra-rare diseases
like primary hyperoxularia. Blandine is also the Executive Sponsor for
the HoLA (Hispanics and Latinos in Novo Nordisk) Employee
Resource Group, which provides Hispanic and Latino perspectives
and promotes education and awareness of patients within the community.
This group also supports Hispanic/Latino employees at Novo Nordisk,
highlighting leaders and role models who can build a strong network.
Blandine believes in philosophies around leadership and
decision-making that capitalize on a company's greatest strength – its
people. She creates the vision and connections that lead to achieving
ambitious and transformational shared goals and values across internal
and external stakeholders, regardless of position or tenure.
Blandine's authenticity and transparency foster collaborative and,
most importantly, safe environments where the right people are in the
right jobs, and everyone can bring their whole selves to work.
Embracing diversity, activating teams and empowering people, and
pioneering new paths forward are her core principles. As a result,
Blandine is able to mobilize teams and stakeholders to solve
large-scale complex issues, resulting in positive disruption and
Blandine is a proven global commercial leader who brings over 25
years of experience in marketing and commercial leadership within the
healthcare/life science industry. She joined Novo Nordisk in 2002 in
the company’s Australia affiliate. Since that time, she has progressed
through roles of escalating responsibility leading global marketing
teams, at the company’s headquarters in Denmark and within the US
affiliate, across both diabetes and obesity therapeutic areas.
Blandine led the establishment of the company’s US obesity business as
Vice President, Obesity Marketing, from 2013 to 2017. She then led the
Obesity business at Novo Nordisk Inc. from 2017 to 2020, where she was
responsible for driving strategies transforming how the world sees,
prevents, and treats the disease. And prior to her current role,
Blandine was Corporate Vice President, Strategy and Rare Disease since
September 1, 2020 and was promoted to Senior Vice President, Strategy
and Rare Disease in January 2023.
Before joining Novo Nordisk, Blandine managed teams and business
opportunities for several international companies across diverse
industries such as technology, health, manufacturing, and education.
Blandine's most important life mandate is to be "Sophie's
mom" and while time will tell, she aspires for this to be her
greater achievement in life.
Blandine studied business with a major in Finance and Accounting as
an undergraduate at the MBA Institute in Paris, France, and has a
Master of International Business from the University of South Carolina.